Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31198846 | 0.85 | SMN1; SMN2 (0.54) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4619201 | 0.85 | SMN1; SMN2 (0.54) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL8316392 | 0.82 | SMN1; SMN2 (0.61) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4672740 | 0.81 | HRH3 (0.51) | HRH3SMN1; SMN2NPC1RAB9AKCNH2 | |
| SCHEMBL13198831 | 0.81 | SMN1; SMN2 (0.63) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL7503285 | 0.81 | SMN1; SMN2 (0.62) | HRH3PDE4BSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL23141990 | 0.81 | LNPEP (0.55) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| Hydrochloric Acid SCHEMBL23141992 | 0.81 | LNPEP (0.55) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4691894 | 0.80 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL4035554 | 0.80 | SMN1; SMN2 (0.72) | PDE4BSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883636-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2008-02-06 | — | — | EP | disclosed |
| US-20060293298-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| WO-2006125665-A1 | SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293298-A1 | Compounds | NQO1, OPRM1, CAT | HRH3 2502/4885PDE4B 296/4885SMN1; SMN2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.